Sign up
Pharma Capital

Wattle Health Australia's orders from Macau and India provide entry into large markets

The company has demonstrated its ability to meet international regulatory requirements.
Picture of milk bottles
January gross sales of $329,000 represented 61% of sales in the December quarter

Wattle Health Australia Ltd’s (ASX: WHA) receipt of its first paid order from a distributor in Macao Special Administrative Region quickly follows its first order from India.

The Macao order enables Wattle Health to serve the domestic market in Macau, while also taking advantage of the large cross-border opportunity into China.

The order was an endorsement of the company’s products in that it covered its entire nutritional range from infant formula to maternal nutritional milk and full cream milk.

Large demand from tourists

Though Macau has a population of approximately 650,000, it is a popular tourist destination with visitors of 36 million per year.

This large tourism market and the geographic proximity to China makes indicates Wattle Health’s entry into Macau is strategically important.

The attainment of China Food and Drug Authority (CFDA) accreditation for the company’s conventional cow infant formula is expected to have a positive impact on sales in 2018.

International footprint and group sales growing

The company is expanding into new international markets and this should have a positive impact on the strong sales growth that is already being achieved.

Wattle Health’s gross sales were $329,000 in January. This represents 35% of sales for FY2017 and 61% of sales in the December quarter.

Track record of meeting regulatory requirements

The company’s entry into India demonstrates that it has the ability to meet the regulatory requirements of international markets.

This effectively opened the door for the company to compete in one of the most populated areas in the world where almost half the population are under the age of 25.

India has an extensive regulatory regime for the importation of food, and Wattle Health has successfully met their strict criteria which has allowed them to enter this lucrative market. 

Register here to be notified of future WHA Company articles
View full WHA profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.